Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%

Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cover at least 80% of their scalp after 36 weeks of treatment.

The results surprised Wall Street analysts and lifted the company’s stock more than 80% in morning trading, with shares trading above $20, near levels seen before earlier setbacks.

Q32 positions bempikibart as a safer and more effective alternative to existing biologic treatments, which can carry infection and heart‑related risks. The success follows a previous failed eczema study and mixed data in an earlier alopecia cohort.